阿卡波糖
医学
餐后
糖尿病
中止
内科学
2型糖尿病
减肥
析因分析
相伴的
胃肠病学
内分泌学
肥胖
作者
Ganesan Arungarinathan,Gerard McKay,Miles Fisher
摘要
Acarbose is an alpha-glucosidase inhibitor acting in the gastrointestinal tract producing modest reductions in postprandial hyperglycaemia, with negligible risk of hypoglycaemia and weight gain. In a subgroup of the United Kingdom Prospective Diabetes Study (UKPDS), acarbose showed glycaemic benefits irrespective of the type of concomitant therapy. Acarbose was shown to produce a significant reduction in the progression to diabetes in patients with impaired glucose tolerance in the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) trial, and in a post-hoc analysis of STOP-NIDDM a reduction in cardiovascular events was observed. Gastrointestinal side effects are the main limiting factor in clinical practice, leading to high rates of non-compliance and discontinuation.
科研通智能强力驱动
Strongly Powered by AbleSci AI